A number of firms have modified their ratings and price targets on shares of Mylan N.V. (NASDAQ: MYL) recently:

  • 10/4/2017 – Mylan N.V. had its price target raised by analysts at BTIG Research from $42.00 to $45.00. They now have a “buy” rating on the stock.
  • 10/3/2017 – Mylan N.V. was upgraded by analysts at BidaskClub from a “sell” rating to a “hold” rating.
  • 10/2/2017 – Mylan N.V. was upgraded by analysts at ValuEngine from a “hold” rating to a “buy” rating.
  • 9/29/2017 – Mylan N.V. had its “buy” rating reaffirmed by analysts at BMO Capital Markets. They now have a $45.00 price target on the stock.
  • 9/8/2017 – Mylan N.V. had its “hold” rating reaffirmed by analysts at Cantor Fitzgerald. They now have a $34.00 price target on the stock.
  • 9/7/2017 – Mylan N.V. was upgraded by analysts at BidaskClub from a “strong sell” rating to a “sell” rating.
  • 9/1/2017 – Mylan N.V. was downgraded by analysts at ValuEngine from a “buy” rating to a “hold” rating.
  • 8/22/2017 – Mylan N.V. was downgraded by analysts at Argus from a “buy” rating to a “hold” rating. They now have a $29.39 price target on the stock, down previously from $47.59. They wrote, “junior version”
  • 8/20/2017 – Mylan N.V. had its “buy” rating reaffirmed by analysts at Mizuho. They now have a $37.00 price target on the stock, down previously from $53.00.
  • 8/16/2017 – Mylan N.V. was upgraded by analysts at Citigroup Inc. from a “neutral” rating to a “buy” rating. They now have a $42.00 price target on the stock, up previously from $36.00.
  • 8/16/2017 – Mylan N.V. was downgraded by analysts at BidaskClub from a “sell” rating to a “strong sell” rating.
  • 8/10/2017 – Mylan N.V. had its “sector perform” rating reaffirmed by analysts at Royal Bank Of Canada. They now have a $32.00 price target on the stock, down previously from $33.00.
  • 8/10/2017 – Mylan N.V. had its “outperform” rating reaffirmed by analysts at BMO Capital Markets. They now have a $45.00 price target on the stock, down previously from $50.00.
  • 8/10/2017 – Mylan N.V. had its “buy” rating reaffirmed by analysts at UBS AG. They now have a $46.00 price target on the stock, down previously from $50.00.
  • 8/9/2017 – Mylan N.V. was given a new $30.00 price target on by analysts at Wells Fargo & Company. They now have a “hold” rating on the stock.
  • 8/9/2017 – Mylan N.V. was given a new $34.00 price target on by analysts at Cantor Fitzgerald. They now have a “hold” rating on the stock.
  • 8/9/2017 – Mylan N.V. had its “hold” rating reaffirmed by analysts at Cowen and Company. They now have a $30.00 price target on the stock, down previously from $43.00.
  • 8/7/2017 – Mylan N.V. had its price target lowered by analysts at Morgan Stanley from $52.00 to $36.00. They now have an “equal weight” rating on the stock.
  • 8/5/2017 – Mylan N.V. was downgraded by analysts at BidaskClub from a “hold” rating to a “sell” rating.

Mylan N.V. (MYL) traded up 19.7359% on Wednesday, hitting $38.9501. 20,774,769 shares of the company were exchanged. The stock has a market capitalization of $20.89 billion, a P/E ratio of 31.4876 and a beta of 1.30. The company has a 50 day moving average price of $31.43 and a 200-day moving average price of $36.46. Mylan N.V. has a 52 week low of $29.39 and a 52 week high of $45.87.

Mylan N.V. (NASDAQ:MYL) last announced its quarterly earnings results on Wednesday, August 9th. The company reported $1.10 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $1.18 by ($0.08). Mylan N.V. had a return on equity of 22.42% and a net margin of 5.51%. The firm had revenue of $2.96 billion during the quarter, compared to the consensus estimate of $3 billion. During the same quarter in the previous year, the firm earned $1.16 EPS. The business’s revenue for the quarter was up 15.7% on a year-over-year basis. On average, equities analysts expect that Mylan N.V. will post $4.52 earnings per share for the current fiscal year.

Mylan N.V. is a global pharmaceutical company. The Company develops, licenses, manufactures, markets and distributes generic and branded generic products for resale by others; specialty pharmaceuticals, and active pharmaceutical ingredients (APIs). It operates through two segments: Generics and Specialty.

Receive News & Ratings for Mylan NV Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mylan NV and related companies with MarketBeat.com's FREE daily email newsletter.